Ann: Invex Granted Key European Patent for Exenatide, page-50

Or it could just be time and the market. Had you put your money elsewhere over the past 12 months you would have made a lot more than parking it here. OPT's share price is struggling for the same reason. Investors know that they can come back to this stock in a few months and pay a comparable price. FYI, I very confidently sold my entire IXC allocation after the Phase 2 result announcement knowing that there'd be this dip between P2 and P3 trials. The instos will jump back in soon - very confident of that. And especially now that the EU patent has been granted.